| National Science Foundation (NSF) | NSF Rapid Response Research (RAPID) funding mechanism for non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge. |
| American Heart Association (AHA) | AHA COVID-19 Coordinating CenterFunding: $150,000Deadline: April 6, 2020 |
| American Heart Association (AHA) | AHA Rapid Response Grant: COVID-19 and Its Cardiovascular ImpactFunding: $100,000Deadline: April 6, 2020 |
NIH ǀ National Institute of Allergy and Infectious Diseases (NIAID)
NOT-AI-20-034 | Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome |
| NIH ǀ National Center for Advancing Translational Sciences (NCATS) NOT-TR-20-011 | Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need |
| NIH ǀ National Institute of General Medical Sciences (NIGMS) NOT-GM-20-025 | Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 |
NIH ǀ National Institute of Allergy and Infectious Diseases (NIAID)
NIH ǀ National Institute of General Medical Sciences (NIGMS) NOT-AI-20-030 | Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) |
| NIH ǀ National Institute on Drug Abuse (NIDA) NOT-DA-20-047 | Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus |
| NIH ǀ National Heart, Lung, and Blood Institute (NHLBI) NOT-HL-20-757 | Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) |
| HHS ǀ Office of Biomedical Advanced Research and Development Authority (BARDA) ǀ Broad Agency Announcement (BAA) | BARDA expanded its standard broad agency announcement to accept proposals for advanced development of diagnostics, vaccines, therapeutics and other medical products for use in the current COVID-19 emergency response and future coronavirus outbreaks |
